

Joaquim Mullo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8838864/publications.pdf>

Version: 2024-02-01

215
papers

22,181
citations

22548

61
h-index

11608

140
g-index

229
all docs

229
docs citations

229
times ranked

13448
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for chronic rhinosinusitis with nasal polyps (<sc>SYNAPSE</sc>): Inâ€depth sinus surgery analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 812-821.	2.7	14
2	Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. Journal of Allergy and Clinical Immunology, 2022, 149, 957-965.e3.	1.5	58
3	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 343-345.e2.	2.0	11
4	Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAIDâ€ERD: Results from two randomized placeboâ€controlled phase 3 trials. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1231-1244.	2.7	45
5	Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1086-1095.e5.	2.0	42
6	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed foodâ€”A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GAÂLEN position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1736-1750.	2.7	21
7	Development and validation of combined symptomâ€medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	2.7	32
8	Twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps. Rhinology, 2022, .	0.7	6
9	Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2211-2221.	2.7	25
10	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	1.4	9
11	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air^Â realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	2.7	17
12	Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1434-1453.e9.	2.0	35
13	Chronic Rhinosinusitis and COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1423-1432.	2.0	18
14	Hedonic perception of odors in children aged 5â€8 years is similar across 18 countries: Preliminary data. International Journal of Pediatric Otorhinolaryngology, 2022, 157, 111129.	0.4	9
15	Reference Gene Validation for RTâ€qPCR in PBMCs from Asthmatic Patients with or without Obesity. Methods and Protocols, 2022, 5, 35.	0.9	2
16	Barcelona Olfactory Test â€ 8: validation of a new test on Spanish population during COVID-19 pandemic. Journal of Investigational Allergology and Clinical Immunology, 2022, 32, 0.	0.6	0
17	Comparison of rhinitis treatments using <sc>MASK</sc>â€airÂ data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	2.7	8
18	Presentation of airway and general symptoms in COVIDâ€19 caused by dominant <sc>SARSâ€CoV</sc>â€2 variants: A followâ€up on <sc>ARIA</sc> consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3440-3444.	2.7	3

#	ARTICLE	IF	CITATIONS
19	Update about Oralair® as a treatment for grass pollen allergic rhinitis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
20	Differences in Inflammatory Cytokine Profile in Obesity-Associated Asthma: Effects of Weight Loss. <i>Journal of Clinical Medicine</i> , 2022, 11, 3782.	1.0	8
21	Direct Costs of Acute Rhinosinusitis in Spain: A Prospective and Observational Study (PROSINUS). <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 481-488.	0.6	3
22	Role of microRNAs in inflammatory upper airway diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1967-1980.	2.7	14
23	Functional Examination of the Upper and Lower Airways in Asthma and Respiratory Allergic Diseases: Considerations in the Post-SARS-CoV-2 Era. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 17-35.	0.6	12
24	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic. An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	2.7	79
25	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	2.7	46
26	ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	2.7	57
27	Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 57-66.	1.1	21
28	Chronic Rhinosinusitis with Nasal Polyps and Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1133-1141.	2.0	148
29	The Debate: Regular Versus As-Needed Use of Intranasal Corticosteroids for a Patient-Centered Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1374-1375.	2.0	3
30	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRS _{swNP}) and biologics: Definitions and management. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 29-36.	1.5	178
31	International consensus statement on allergy and rhinology: rhinosinusitis 2021. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 213-739.	1.5	398
32	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 413-414.	1.5	2
33	Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases. <i>World Allergy Organization Journal</i> , 2021, 14, 100498.	1.6	27
34	Spices to Control COVID-19 Symptoms: Yes, but Not Only. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 489-495.	0.9	23
35	Chemosensory dysfunction in COVID-19 out-patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 695-702.	0.8	44
36	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 324-338.	0.9	33

#	ARTICLE	IF	CITATIONS
37	Self-reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China. <i>Current Medical Science</i> , 2021, 41, 14-23.	0.7	44
38	Chemosensory Dysfunction in Patients with COVID-19: What Do We Learn from the Global Outbreak?. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 6.	2.4	11
39	Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis. <i>Rhinology</i> , 2021, 59, 2-9.	0.7	14
40	Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 27.	2.4	9
41	Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. <i>Rhinology</i> , 2021, 59, 0-0.	0.7	20
42	High Frequency of Smell and Taste Dysfunction in Health Care Professionals With COVID-19 Working in Allergy Departments. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 151-161.	0.6	4
43	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	1.4	8
44	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-AAACI-GA ² LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	2.7	31
45	ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID-19 protective factor?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2904-2907.	2.7	13
46	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 584-592.e1.	0.5	59
47	Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19 " a Primer for Clinicians. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 38.	2.4	7
48	ARIA-AAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	1.4	24
49	Eicosanoid dysregulation and type 2 inflammation in AERD. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1157-1160.	1.5	13
50	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	2.7	16
51	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-Air®. <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	1.4	31
52	Loss of smell in patients with traumatic brain injury is associated with neuropsychiatric behavioral alterations. <i>Brain Injury</i> , 2021, 35, 1418-1424.	0.6	2
53	Predictive factors for invasive fungal rhinosinusitis in diabetic patients: Systematic review and data re-analysis. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2021, 39, 1-8.	0.2	2
54	Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2577-2586.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	1.5	272
56	Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 148-157.	2.7	75
57	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2020, 10, 1.	1.4	110
58	Lack of additive benefit of oral steroids on short-term postoperative outcomes in nasal polyposis. <i>Laryngoscope</i> , 2020, 130, 2742-2747.	1.1	11
59	Olfactory dysfunction during COVID-19 pandemic. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 403-408.	0.1	8
60	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 463-464.	1.5	0
61	Prodromal Parkinson disease in patients with idiopathic hyposmia. <i>Journal of Neurology</i> , 2020, 267, 3673-3682.	1.8	12
62	<p>MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 633-645.	1.5	8
63	The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 61.	2.4	127
64	Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 754-764.	0.9	2
65	Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. <i>Clinical and Molecular Allergy</i> , 2020, 18, 15.	0.8	11
66	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. <i>Clinical and Translational Allergy</i> , 2020, 10, 62.	1.4	34
67	Olfactory Dysfunction in a Mexican Population Outside of COVID-19 Pandemic: Prevalence and Associated Factors (the OLFAMEX Study). <i>Current Allergy and Asthma Reports</i> , 2020, 20, 78.	2.4	4
68	Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials. , 2020, , .		0
69	Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 951-958.	1.5	7
70	Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2867-2878.	2.7	45
71	Validation of the ARIA items to assess allergic rhinitis control (ARIA). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2964-2966.	2.7	2
72	Olfactory Dysfunction in the COVID-19 Outbreak. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 317-326.	0.6	73

#	ARTICLE	IF	CITATIONS
73	Rhinitis Phenotypes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1492-1503.	2.0	27
74	Psychophysical olfactory testing in COVID-19: is smell function really impaired in nearly all patients?. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 951-952.	1.5	11
75	Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 28.	2.4	43
76	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	1.4	97
77	Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 595-605.	1.5	380
78	Smell and Taste Dysfunction in COVID-19 Is Associated With Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 346-357.	0.6	81
79	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	2.7	114
80	The sense of smell in chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 773-776.	1.5	49
81	Pérdida del sentido del olfato durante la pandemia COVID-19. <i>Medicina Clínica</i> , 2020, 155, 403-408.	0.3	5
82	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	2.7	32
83	Integrated mRNA and microRNA transcriptome profiling during differentiation of human nasal polyp epithelium reveals an altered ciliogenesis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2548-2561.	2.7	21
84	Executive Summary of EPOS 2020 Including Integrated Care Pathways. <i>Rhinology</i> , 2020, 58, 82-111.	0.7	245
85	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	2.7	87
86	Rhinology Future Debates 2018, a EUFOREA Report. <i>Rhinology</i> , 2020, 58, 0-0.	0.7	6
87	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. <i>Rhinology</i> , 2020, 58, 1-464.	0.7	1,555
88	Dupilumab Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps Regardless of Sinonasal Surgery History – Pooled Results From SINUS-24 and SINUS-52 Phase 3 Trials. , 2020, 99, .		0
89	Immune response to fungi in diabetic patients with invasive fungal rhinosinusitis. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2020, 38, 233-238.	0.2	3
90	The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. <i>Rhinology</i> , 2019, 57, 0-0.	0.7	36

#	ARTICLE	IF	CITATIONS
91	ARIA masterclass 2018: From guidelines to real-life implementation. <i>Rhinology</i> , 2019, 57, 0-0.	0.7	6
92	Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2462-2465.e1.	2.0	101
93	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	0.9	22
94	Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. <i>Rhinology</i> , 2019, 58, 0-0.	0.7	21
95	Clinically relevant effect of rupatadine 20Âmg and 10Âmg in seasonal allergic rhinitis: a pooled responder analysis. <i>Clinical and Translational Allergy</i> , 2019, 9, 50.	1.4	5
96	Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1338.	1.0	26
97	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	0.6	11
98	Assessment of craniofacial hyperhidrosis and flushing by sphenopalatine blockade - a randomized trial. <i>Rhinology</i> , 2019, 58, 0-0.	0.7	2
99	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. <i>Lancet, The</i> , 2019, 394, 1638-1650.	6.3	812
100	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	0.6	15
101	EUFOREA consensus on biologics for CRSwNP with or without asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2312-2319.	2.7	239
102	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	1.5	101
103	Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2447-2449.e2.	2.0	56
104	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	1.4	81
105	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	2.7	140
106	Patient Advisory Board for Chronic Rhinosinusitis â€” A EUFOREA initiative. <i>Rhinology</i> , 2019, 57, 0-0.	0.7	8
107	Self-perception of olfactory dysfunction is associated with history of Traumatic Brain Injury: post-hoc analysis from the OLFACAT survey. <i>Rhinology</i> , 2019, 57, 460-468.	0.7	4
108	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2511-2523.	2.0	44

#	ARTICLE	IF	CITATIONS
109	Diagnosis and management of <scp>NSAID</scp>â€œExacerbated Respiratory Disease (Nâ€œ<scp>ERD</scp>)â€œ”a <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 28-39.	2.7	247
110	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€œ. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	2.7	52
111	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	1.4	73
112	Antileukotrienes improve nasoâ€œcular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope, 2019, 129, 551-557.	1.1	20
113	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	1.5	103

114

#	ARTICLE	IF	CITATIONS
127	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 505-510.	2.7	77
128	Lack of long-term addition effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps. <i>Laryngoscope</i> , 2018, 128, 1743-1751.	1.1	19
129	... International Forum of Allergy and Rhinology, 2018, 8, 108-124.		
130	Cyclamen europaeum improves the effect of oral antibiotics on exacerbations and recurrences of chronic rhinosinusitis: a real-life observational study (CHRONOS). <i>Acta Otorhinolaryngologica Italica</i> , 2018, 38, 115-123.	0.7	5
131	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	1.4	104
132	Olfactory Training in Post-Traumatic Smell Impairment: Mild Improvement in Threshold Performances: Results from a Randomized Controlled Trial. <i>Journal of Neurotrauma</i> , 2018, 35, 2641-2652.	1.7	36
133	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 42-44.	0.6	37
134	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. <i>World Allergy Organization Journal</i> , 2018, 11, 15.	1.6	33
135	mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. <i>Rhinology</i> , 2018, 56, 209-215.	0.7	41
136	Electronic Clinical Decision Support System for allergic rhinitis management: MASK eCDSS. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1640-1653.	1.4	61
137	Development of an International Odor Identification Test for Children: The Universal Sniff Test. <i>Journal of Pediatrics</i> , 2018, 198, 265-272.e3.	0.9	72
138	Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. , 2018, 27, 56.		2
139	Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK rhinitis study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 857-865.	2.7	93
140	Influence of nasal septum deformity on nasal obstruction, disease severity, and medical treatment response among children and adolescents with persistent allergic rhinitis. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2017, 95, 145-154.	0.4	16
141	Work productivity in rhinitis using cell phones: The MASK pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1475-1484.	2.7	69
142	Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: A real-life study. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 438-445.	1.1	33
143	Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1657-1665.	2.7	193
144	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines 2016 revision. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 950-958.	1.5	1,199

#	ARTICLE	IF	CITATIONS
145	A possible role of stem cells in nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1868-1873.	2.7	14
146	Olfactory function in an excitotoxic model for secondary neuronal degeneration: Role of dopaminergic interneurons. <i>Neuroscience</i> , 2017, 364, 28-44.	1.1	14
147	Validation of the MASK® rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1526-1533.	1.4	75
148	Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. <i>Clinical and Translational Allergy</i> , 2017, 7, 17.	1.4	107
149	Olfaction in patients with allergic rhinitis: an indicator of successful MP&AzeFlu therapy. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 287-292.	1.5	15
150	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRAIL report. <i>Clinical and Translational Allergy</i> , 2017, 7, 37.	1.4	36
151	Effects of Rupatadine on Platelet-Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 161-168.	0.6	14
152	Position paper on olfactory dysfunction. <i>Rhinology</i> , 2017, 54, 1-30.	0.7	478
153	Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe. <i>Rhinology</i> , 2017, 55, 34-38.	0.7	29
154	EUFOR&A Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. <i>Rhinology</i> , 2017, 55, 202-210.	0.7	36
155	Allergy rhinitis: similarities and differences between children and adults. <i>Rhinology</i> , 2017, 55, 326-331.	0.7	19
156	MicroRNA in United Airway Diseases. <i>International Journal of Molecular Sciences</i> , 2016, 17, 716.	1.8	23
157	Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis. <i>Sinusitis</i> , 2016, 1, 24-43.	0.2	3
158	Nasal polyps in patients with asthma: prevalence, impact, and management challenges. <i>Journal of Asthma and Allergy</i> , 2016, 9, 45.	1.5	72
159	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. <i>Clinical and Translational Allergy</i> , 2016, 6, 41.	1.4	24
160	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	1.4	121
161	Rupatadine: global safety evaluation in allergic rhinitis and urticaria. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1439-1448.	1.0	22
162	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	1.4	47

#	ARTICLE	IF	CITATIONS
163	Allergic rhinitis causes loss of smell in children: The <sc>OLFAPEdRIAL</sc> study. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 867-870.	1.1	23
164	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. <i>World Allergy Organization Journal</i> , 2016, 9, 33.	1.6	87
165	Low E-prostanoid 2 receptor levels and deficient induction of the IL-1 β /IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 99-107.e7.	1.5	44
166	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 657-669.	0.9	14
167	Long-term outcomes of endoscopic endonasal approach for skull base surgery: a prospective study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1809-1817.	0.8	34
168	Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 469.	3.8	628
169	Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1449-1456.e4.	1.5	833
170	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	2.7	160
171	Nasal polyps, aspirin sensitivity, and late onset asthma are crucial to identify severe asthma. <i>ClinicalTrials.gov id : nct01513837. Clinical and Translational Allergy</i> , 2015, 5, O3.	1.4	2
172	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. <i>Clinical and Translational Allergy</i> , 2015, 5, 39.	1.4	82
173	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. <i>Clinical and Translational Allergy</i> , 2015, 5, 36.	1.4	23
174	Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma. <i>PLoS ONE</i> , 2015, 10, e0125443.	1.1	11
175	Update on rupatadine in the management of allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1-24.	2.7	53
176	MicroRNA: Endotyping United Airways?. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 10-12.	0.9	4
177	Reconstituted Human Upper Airway Epithelium as 3-D In Vitro Model for Nasal Polyposis. <i>PLoS ONE</i> , 2014, 9, e100537.	1.1	29
178	Rhinosinusitis and Nasal Polyps in Aspirin-Exacerbated Respiratory Disease. <i>Immunology and Allergy Clinics of North America</i> , 2013, 33, 163-176.	0.7	61
179	Specialist-based treatment reduces the severity of allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2013, 43, 723-729.	1.4	14
180	Assessment of nasal obstruction: Correlation between subjective and objective techniques. <i>Allergologia Et Immunopathologia</i> , 2013, 41, 397-401.	1.0	48

#	ARTICLE	IF	CITATIONS
181	Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1-7.	2.7	169
182	Pharmacoeconomics of Cyclamen europaeum in the management of acute rhinosinusitis. Laryngoscope, 2013, 123, 2620-2625.	1.1	12
183	Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design. Allergy, Asthma and Clinical Immunology, 2013, 9, 43.	0.9	16
184	Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. International Archives of Allergy and Immunology, 2013, 161, 369-377.	0.9	104
185	Platelet-activating Factor Nasal Challenge Induces Nasal Congestion and Reduces Nasal Volume in Both Healthy Volunteers and Allergic Rhinitis Patients. American Journal of Rhinology and Allergy, 2013, 27, e48-e52.	1.0	16
186	Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open, 2012, 2, e001256.	0.8	162
187	Validation of the modified allergic rhinitis and its impact on asthma (<scp>ARIA</scp>) severity classification in allergic rhinitis children: the <scp>PEDRIAL</scp> study. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1437-1442.	2.7	45
188	Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology, 2012, 50, 339-352.	0.7	28
189	Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology, 2012, 50, 339-352.	0.7	42
190	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,665
191	Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects. Respiratory Medicine, 2011, 105, 218-225.	1.3	11
192	Combined Oral and Intranasal Corticosteroid Therapy: An Advance in the Management of Nasal Polyposis?. Annals of Internal Medicine, 2011, 154, 365.	2.0	16
193	Viruses and bacteria in acute asthma exacerbations â€“ A GA²LENâ€™DARE* systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 458-468.	2.7	237
194	Diagnostic tools in Rhinology EAACI position paper. Clinical and Translational Allergy, 2011, 1, 2.	1.4	156
195	Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respiratory Research, 2011, 12, 23.	1.4	17
196	Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1609-1613.	2.7	21
197	Importance of glucocorticoid receptors in upper and lower airways. Frontiers in Bioscience - Landmark, 2010, 15, 789.	3.0	28
198	GA²LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma â€™epidemicâ€™. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 969-977.	2.7	95

#	ARTICLE	IF	CITATIONS
199	Efficacy of desloratadine in intermittent allergic rhinitis: a GALEN study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1516-1523.	2.7	55
200	Corticosteroid Treatment in Chronic Rhinosinusitis: The Possibilities and the Limits. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, 657-668.	0.7	86
201	A survey of the burden of allergic rhinitis in Spain. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2009, 19, 27-34.	0.6	38
202	Relevance of COX-2 gene expression in dementia with lewy bodies associated with Alzheimer pathology. <i>Movement Disorders</i> , 2008, 23, 804-810.	2.2	9
203	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	2.7	3,827
204	Rupatadine in allergic rhinitis and chronic urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 5-28.	2.7	458
205	Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1377-1386.	2.7	50
206	Patient Perceptions of Allergic Rhinitis and Quality of Life. <i>World Allergy Organization Journal</i> , 2008, 1, 138-144.	1.6	60
207	A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 359-365.	1.5	86
208	A survey of the burden of allergic rhinitis in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 17-25.	2.7	392
209	Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. <i>Clinical and Experimental Allergy</i> , 2006, 36, 52-58.	1.4	39
210	Expression of the glucocorticoid receptor alpha and beta isoforms in human nasal mucosa and polyp epithelial cells. <i>Respiratory Medicine</i> , 2003, 97, 90-96.	1.3	48
211	Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 824-830.	1.5	59
212	Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. <i>Respiratory Medicine</i> , 2000, 94, 428-431.	1.3	25
213	Effects of topical anti-inflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium. <i>Clinical and Experimental Allergy</i> , 1997, 27, 1432-41.	1.4	11
214	Failure of frusemide to increase production of prostaglandin E2 in human nasal mucosa in vivo.. <i>Thorax</i> , 1993, 48, 260-263.	2.7	5
215	M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. <i>Journal of Applied Physiology</i> , 1992, 73, 2069-2073.	1.2	38